Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
MUMBAI - Indian drug maker Glenmark Pharmaceuticals' lead molecule for neuropathic pain, osteoarthritis and other inflammatory pain will enter Phase I trials shortly, the company announced, after filing for Phase I approval with European regulatory authorities